JP2011501176A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011501176A5 JP2011501176A5 JP2010530497A JP2010530497A JP2011501176A5 JP 2011501176 A5 JP2011501176 A5 JP 2011501176A5 JP 2010530497 A JP2010530497 A JP 2010530497A JP 2010530497 A JP2010530497 A JP 2010530497A JP 2011501176 A5 JP2011501176 A5 JP 2011501176A5
- Authority
- JP
- Japan
- Prior art keywords
- disease
- inflammatory
- symptoms
- patient
- disease progression
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 208000024891 symptom Diseases 0.000 claims description 14
- 102100022464 5'-nucleotidase Human genes 0.000 claims description 8
- 101000678236 Homo sapiens 5'-nucleotidase Proteins 0.000 claims description 8
- 206010063837 Reperfusion injury Diseases 0.000 claims description 7
- 230000002757 inflammatory effect Effects 0.000 claims description 7
- 201000010099 disease Diseases 0.000 claims description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 6
- 210000000056 organ Anatomy 0.000 claims description 6
- 238000002054 transplantation Methods 0.000 claims description 6
- 239000012530 fluid Substances 0.000 claims description 5
- 208000010125 myocardial infarction Diseases 0.000 claims description 5
- 238000001356 surgical procedure Methods 0.000 claims description 5
- 230000000451 tissue damage Effects 0.000 claims description 5
- 231100000827 tissue damage Toxicity 0.000 claims description 5
- 206010061818 Disease progression Diseases 0.000 claims description 4
- 208000034486 Multi-organ failure Diseases 0.000 claims description 4
- 206010051379 Systemic Inflammatory Response Syndrome Diseases 0.000 claims description 4
- 206010069351 acute lung injury Diseases 0.000 claims description 4
- 230000005750 disease progression Effects 0.000 claims description 4
- 208000012947 ischemia reperfusion injury Diseases 0.000 claims description 4
- 208000029744 multiple organ dysfunction syndrome Diseases 0.000 claims description 4
- 208000027866 inflammatory disease Diseases 0.000 claims description 3
- 230000001154 acute effect Effects 0.000 claims description 2
- 239000000090 biomarker Substances 0.000 claims description 2
- 238000012544 monitoring process Methods 0.000 claims description 2
- 208000006011 Stroke Diseases 0.000 claims 1
- 230000002411 adverse Effects 0.000 claims 1
- 230000003247 decreasing effect Effects 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 description 6
- 201000011510 cancer Diseases 0.000 description 6
- 208000023275 Autoimmune disease Diseases 0.000 description 3
- 206010027476 Metastases Diseases 0.000 description 3
- 230000009401 metastasis Effects 0.000 description 3
- 230000010410 reperfusion Effects 0.000 description 3
- 206010061623 Adverse drug reaction Diseases 0.000 description 2
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 2
- 208000010718 Multiple Organ Failure Diseases 0.000 description 2
- 230000000172 allergic effect Effects 0.000 description 2
- 208000010668 atopic eczema Diseases 0.000 description 2
- 208000037979 autoimmune inflammatory disease Diseases 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 208000011231 Crohn disease Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000004968 inflammatory condition Effects 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FI20070795 | 2007-10-24 | ||
| FI20070795A FI20070795A0 (fi) | 2007-10-24 | 2007-10-24 | Uusi biomarkkeri sairauksien kehittämisen tarkkailuun ja terapioiden tehon arviointiin |
| PCT/FI2008/050576 WO2009053523A1 (en) | 2007-10-24 | 2008-10-15 | A new biomarker for monitoring development of diseases and assessing the efficacy of therapies |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012098081A Division JP5619810B2 (ja) | 2007-10-24 | 2012-04-23 | 疾患の進展をモニターするための、および治療法の有効性を評価するための新規なバイオマーカー |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2011501176A JP2011501176A (ja) | 2011-01-06 |
| JP2011501176A5 true JP2011501176A5 (enExample) | 2012-04-19 |
| JP4982610B2 JP4982610B2 (ja) | 2012-07-25 |
Family
ID=38656804
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010530497A Expired - Fee Related JP4982610B2 (ja) | 2007-10-24 | 2008-10-15 | 疾患の進展をモニターするための、および治療法の有効性を評価するための新規なバイオマーカー |
| JP2012098081A Expired - Fee Related JP5619810B2 (ja) | 2007-10-24 | 2012-04-23 | 疾患の進展をモニターするための、および治療法の有効性を評価するための新規なバイオマーカー |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012098081A Expired - Fee Related JP5619810B2 (ja) | 2007-10-24 | 2012-04-23 | 疾患の進展をモニターするための、および治療法の有効性を評価するための新規なバイオマーカー |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20100209942A1 (enExample) |
| EP (2) | EP2201376B1 (enExample) |
| JP (2) | JP4982610B2 (enExample) |
| KR (2) | KR20100059902A (enExample) |
| CA (1) | CA2702635A1 (enExample) |
| CY (2) | CY1113403T1 (enExample) |
| DK (2) | DK2503338T3 (enExample) |
| ES (2) | ES2389751T3 (enExample) |
| FI (1) | FI20070795A0 (enExample) |
| HR (2) | HRP20120743T1 (enExample) |
| PL (2) | PL2503338T3 (enExample) |
| PT (2) | PT2201376E (enExample) |
| SI (2) | SI2503338T1 (enExample) |
| WO (1) | WO2009053523A1 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3358354B1 (en) | 2008-01-18 | 2020-07-15 | President and Fellows of Harvard College | Methods of detecting signatures of disease or conditions in bodily fluids |
| MX382244B (es) | 2010-07-23 | 2025-03-13 | Harvard College | Metodos para detectar firmas de enfermedad o condiciones en fluidos corporales |
| CA2806293A1 (en) | 2010-07-23 | 2012-01-26 | President And Fellows Of Harvard College | Methods of detecting autoimmune or immune-related diseases or conditions |
| EP2596349B1 (en) | 2010-07-23 | 2017-12-13 | President and Fellows of Harvard College | Methods of detecting cardiovascular diseases or conditions |
| SG10201505724SA (en) | 2010-07-23 | 2015-09-29 | Harvard College | Methods of detecting diseases or conditions using phagocytic cells |
| US20130203624A1 (en) | 2010-07-23 | 2013-08-08 | President And Fellows Of Harvard College | Methods of Detecting Prenatal or Pregnancy-Related Diseases or Conditions |
| SG11201408383SA (en) | 2012-06-15 | 2015-01-29 | Harry Stylli | Methods of detecting diseases or conditions using circulating diseased cells |
| CN104603289A (zh) | 2012-06-15 | 2015-05-06 | 哈里·斯泰利 | 检测疾病或病状的方法 |
| DK2956772T3 (en) * | 2013-02-14 | 2018-08-13 | Faron Pharmaceuticals Oy | A PROCEDURE FOR DETERMINING ACUTE LUNG FAILURE (ARDS) RELATED BIOMARKERS, A PROCEDURE FOR MONITORING DEVELOPMENT AND TREATMENT OF ARDS BY A PATIENT |
| EP4202441A3 (en) | 2013-03-09 | 2023-07-26 | Immunis.AI, Inc. | Gene expression profile in macrophages for the diagnosis of cancer |
| WO2014164362A1 (en) | 2013-03-09 | 2014-10-09 | Harry Stylli | Methods of detecting prostate cancer |
| US10626464B2 (en) | 2014-09-11 | 2020-04-21 | Cell Mdx, Llc | Methods of detecting prostate cancer |
| PL3221346T3 (pl) | 2014-11-21 | 2021-03-08 | Bristol-Myers Squibb Company | Przeciwciała ze zmodyfikowanym regionem stałym łańcucha ciężkiego |
| TWI711630B (zh) | 2014-11-21 | 2020-12-01 | 美商必治妥美雅史谷比公司 | 抗ｃｄ７３抗體及其用途 |
| GB201706747D0 (en) * | 2017-04-27 | 2017-06-14 | Queen Mary | Method and apparatus for determining the efficacy of statins for treating inflammatory diseases in idividual patients |
| GB201715115D0 (en) | 2017-09-19 | 2017-11-01 | Univ London Queen Mary | Methods for assessing risk of cardiovascular disease and methods and compounds for use in treating or preventing cardiovascular disease |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0854934A4 (en) * | 1995-08-18 | 2000-09-06 | Donald W Landry | DETECTION OF ORGANIC COMPOUNDS BY REGULATION OF ANTIBODY CATALYZED REACTIONS |
| AU7310496A (en) * | 1995-10-13 | 1997-04-30 | Imperial College Of Science, Technology And Medicine | Methods for predicting the outcome of persistent hbv infection and the outcome of cytokine therapy |
| HUP0002003A3 (en) * | 2000-05-24 | 2003-01-28 | Pronuk Biotechnologia Kft | Process and reagent-kit for determining of 5'-nucleotidase activity |
| CA2439961A1 (en) * | 2001-03-27 | 2002-10-03 | Zymogenetics, Inc. | Human cytokine receptor |
| WO2004079013A1 (en) * | 2003-03-03 | 2004-09-16 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Ecto-5’-nucleotidase (cd73) used in the diagnosis and the treatment of pancreatic cancer |
| EP1608400B1 (en) * | 2003-03-28 | 2010-06-23 | Faron Pharmaceuticals OY | Elevation of adenosine level by cytokine-induced expression of cd73 |
| FI20030467A0 (fi) * | 2003-03-28 | 2003-03-28 | Sirpa Jalkanen | Menetelmä tulehdustilojen hoitamiseen |
| CN1835962A (zh) * | 2003-06-03 | 2006-09-20 | 加利福尼亚大学董事会 | 利用乙酰化二糖治疗疾病的组合物与方法 |
| ATE520979T1 (de) * | 2005-08-24 | 2011-09-15 | Bristol Myers Squibb Co | Biomarker und verfahren zur bestimmung der empfindlichkeit gegenüber modulatoren des egf(epidermal growth factor)-rezeptors |
| FI20051003A0 (fi) | 2005-10-07 | 2005-10-07 | Faron Pharmaceuticals Oy | Menetelmä iskemiareperfuusiovaurion tai monielinhäiriön hoitamiseksi tai estämiseksi |
| EP2021350B1 (en) * | 2006-03-21 | 2016-12-21 | Rheinische Friedrich-Wilhelms-Universität Bonn | Phosphorylated a2a receptor agonists |
| CA2657576C (en) * | 2006-07-14 | 2023-10-31 | The Regents Of The University Of California | Cancer biomarkers and methods of use thereof |
-
2007
- 2007-10-24 FI FI20070795A patent/FI20070795A0/fi not_active Application Discontinuation
-
2008
- 2008-10-15 JP JP2010530497A patent/JP4982610B2/ja not_active Expired - Fee Related
- 2008-10-15 ES ES08842581T patent/ES2389751T3/es active Active
- 2008-10-15 CA CA2702635A patent/CA2702635A1/en not_active Abandoned
- 2008-10-15 EP EP08842581A patent/EP2201376B1/en active Active
- 2008-10-15 HR HRP20120743AT patent/HRP20120743T1/hr unknown
- 2008-10-15 SI SI200831377T patent/SI2503338T1/sl unknown
- 2008-10-15 PL PL12002502T patent/PL2503338T3/pl unknown
- 2008-10-15 ES ES12002502.8T patent/ES2532361T3/es active Active
- 2008-10-15 DK DK12002502T patent/DK2503338T3/en active
- 2008-10-15 PL PL08842581T patent/PL2201376T3/pl unknown
- 2008-10-15 WO PCT/FI2008/050576 patent/WO2009053523A1/en not_active Ceased
- 2008-10-15 KR KR1020107006430A patent/KR20100059902A/ko not_active Ceased
- 2008-10-15 US US12/679,785 patent/US20100209942A1/en not_active Abandoned
- 2008-10-15 EP EP12002502.8A patent/EP2503338B1/en active Active
- 2008-10-15 PT PT08842581T patent/PT2201376E/pt unknown
- 2008-10-15 SI SI200830723T patent/SI2201376T1/sl unknown
- 2008-10-15 KR KR1020167005473A patent/KR20160029869A/ko not_active Ceased
- 2008-10-15 PT PT12002502T patent/PT2503338E/pt unknown
- 2008-10-15 DK DK08842581.4T patent/DK2201376T3/da active
-
2012
- 2012-04-23 JP JP2012098081A patent/JP5619810B2/ja not_active Expired - Fee Related
- 2012-10-04 CY CY20121100924T patent/CY1113403T1/el unknown
-
2015
- 2015-02-16 HR HRP20150181TT patent/HRP20150181T1/hr unknown
- 2015-03-06 CY CY20151100234T patent/CY1116089T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Martinez et al. | Idiopathic pulmonary fibrosis | |
| Nadeem et al. | Serum inflammatory markers in obstructive sleep apnea: a meta-analysis | |
| JP2016118568A5 (enExample) | ||
| BR112014014960A2 (pt) | métodos para o diagnóstico da doença de alzheimer | |
| HRP20120743T1 (hr) | Novi biomarker za nadzor razvoja bolesti i procjenu uäśinkovitosti lijeäśenja | |
| Paplińska et al. | Expression of eotaxins in the material from nasal brushing in asthma, allergic rhinitis and COPD patients | |
| Aleem et al. | Correlation of C-reactive protein levels with severity of chronic urticaria | |
| Zeng et al. | Elevated HMGB1-related interleukin-6 is associated with dynamic responses of monocytes in patients with active pulmonary tuberculosis | |
| Juel et al. | Systemic and ocular long pentraxin 3 in patients with age-related macular degeneration | |
| JP2016502406A5 (enExample) | ||
| JP2018536152A5 (enExample) | ||
| Wei et al. | Predictive value of the serum matrix metalloproteinase-9 level on hepatic encephalopathy in patients with chronic liver disease | |
| Mkrtchyan et al. | Involvement of anomalous apoptosis in impairments to synaptic plasticity in post-traumatic stress disorder | |
| Sandri et al. | Transcriptomic, translatomic, and proteomic profiling platform discovers a physiological hallmark of COPD-associated lung cancer | |
| Parvanescu et al. | Gout-risks, comorbidities and associations | |
| Orlova et al. | Extrinsic interstitial lung disease activity markers | |
| Belal et al. | Pentraxin 3 is Increased Early in Blood of Patients with Cerebral Stroke and Predicts its Severity. | |
| Niaz et al. | Association of serum resistin with lipids in hypertensives and coronary artery disease patients | |
| Holz et al. | Reproducibility Of Serum Biomarkers And Relationship To Airway Inflammation Following LPS Challenge In Healthy Volunteers | |
| Scarpa et al. | Autophagy, Apoptosis, Cell Proliferation And Ceramide Expression In Lung Parenchyma Of Subjects With Chronic Obstructive Pulmonary Disease (COPD) | |
| Tew et al. | Serum Type 2 Chemokines In Chronic Obstructive Pulmonary Disease (COPD) Subjects In The Subpopulations And Intermediate Outcomes In COPD Study (SPIROMICS) | |
| Cheng | Effects With Allergic Phenotypes Using Blood Eosinophilic Counts And Ige Levels In Patients With COPD | |
| Zhang et al. | D41 COPD: BIOMARKERS IN STABLE DISEASE AND EXACERBATIONS: Increased Serum Levels Of Lipocalin 1 And 2 In Patients With Stable Chronic Obstructive Pulmonary Disease | |
| Smirnova et al. | Stratification Of Chronic Lung Allograft Dysfunction Phenotypes Using Proteomic Profiling Of Bronchoalveolar Lavage-Fluid | |
| Seys | Mucosal immunity in COPD: from mucociliary dysfunction to lymphoid follicles |